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We have developed a rapid magnetic microparticle-based detection strategy for malarial biomarkers
Plasmodium lactate dehydrogenase (pLDH) and Plasmodium falciparum histidine-rich protein II (PfHRPII).
In this assay, magnetic particles functionalized with antibodies speciﬁc for pLDH and PfHRPII as well as
detection antibodies with distinct enzymes for each biomarker are added to parasitized lysed blood
samples. Sandwich complexes for pLDH and PfHRPII form on the surface of the magnetic beads, which
are washed and sequentially re-suspended in detection enzyme substrate for each antigen. The devel-
oped simultaneous capture and sequential detection (SCSD) assay detects both biomarkers in samples as
low as 2.0 parasites/ml, an order of magnitude below commercially available ELISA kits, has a total in-
cubation time of 35 min, and was found to be reproducible between users over time. This assay provides
a simple and efﬁcient alternative to traditional 96-well plate ELISAs, which take 5–8 h to complete and
are limited to one analyte. Further, the modularity of the magnetic bead-based SCSD ELISA format could
serve as a platform for application to other diseases for which multi-biomarker detection is advanta-
geous.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Enzyme-linked immunosorbent assays (ELISAs) are the gold
standard laboratory technique for quantitative and qualitative
protein detection, serving as both powerful research tools and
clinical diagnostics. These highly sensitive assays are typically
performed in a microtiter plate, utilizing surface-bound antigen or
antibody to bind a protein analyte and enzyme-conjugated, target-
speciﬁc antibodies for detection. Although traditional singleplex
ELISAs are laboratory “workhorses” for sensitive and speciﬁc pro-
tein detection, they require 5–8 h for completion and several in-
cubation steps to ultimately develop signal. Further, conventional
ELISAs are limited to detecting just one analyte from a single
sample.
While traditional ELISAs are useful for diagnoses arising from
one biomarker, diseases requiring multi-analyte detection to
identify or inform treatment have led to the development of
multiplexed immunoassays. A multiplexed immunoassay utilizes
the same “sandwich” format (capture antibody, sample, detectionr B.V. This is an open access article
. Wright).
stitute of Infectious Diseases,antibody) as a conventional singleplex ELISA, except the former
usually adopts ﬂuorescent or chemiluminescent reporter systems
rather than ampliﬁcation of a colorimetric substrate by enzymes
[1]. Two common formats for multiplexed immunoassays include
planar arrays and bead-based suspension assays [2]. In typical,
commercially available planar arrays (Quansys, MSDs), microliter
volumes of capture antibodies for multiple protein biomarkers are
printed discretely onto two-dimensional supports, such as slides
or microtiter plates, using a high-resolution printer. The functio-
nalized supports are then treated with sample, followed by re-
porter-labeled antibody. Signal is detected using a high-resolution
scanner or ﬂuorescence microscope [1]. In addition to multi-
plexing capabilities, planar micro-array immunoassays beneﬁt
from ambient analyte theory. According to ambient analyte theory,
reducing the concentration of capture antibodies results in in-
creased antibody binding site occupancy and thus higher assay
sensitivity [3,4]. However, these beneﬁts are often off-set by mass
transport limitations [1].
In contrast to planar arrays, bead-based suspension im-
munoassays are advantageous because they overcome mass
transport limitations via active mixing throughout the liquid
sample [5]. In a typical bead-based suspension immunoassay
(Luminex™, Bio-PlexPro™, Cytometric Bead Arrays), ﬂuorescent
microbeads are functionalized with capture antibodies, mixed
with a sample, and subsequently mixed with ﬂuorescently-taggedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cytometric methods. Multiplexing capabilities arise when target-
speciﬁc antibodies are functionalized to microbeads with varying
ﬂuorescent signatures distinguishable by ﬂow cytometry [6].
There are several disadvantages to current multiplexed im-
munoassays. Both planar and bead-based immunoassays require
laboratory infrastructure beyond that needed to perform single-
plex conventional ELISAs; planar micro-array assays require high-
resolution ﬂuorescence scanners, and bead-based immunoassays
require ﬂow cytometric instrumentation for detection [1]. Further,
planar micro-arrays require several addition, wash, and incubation
steps totaling up to 3 h [7]. Commercially available bead-based
suspension assays often require 3–4 h for completion, up to 1 h
dedicated to the detection step [8]. To address these pitfalls, we
have developed a magnetic bead-based ELISA in which two bio-
markers are simultaneously captured and sequentially detected in
less than 1 h with no laboratory infrastructure beyond what is
required to perform a conventional singleplex well-plate ELISA.
We applied the developed magnetic bead-based ELISA to the
detection of two malarial biomarkers: (1) Plasmodium lactate de-
hydrogenase (pLDH), and (2) Plasmodium falciparum histidine-rich
protein II (PfHRPII). Malaria, a mosquito-borne infectious disease
caused by Plasmodium protozoan parasites, claimed over 400,000
lives in 2015 [9]. Accurate diagnosis of malaria is imperative for
deﬁning disease prevalence and distribution as well as monitoring
impact of interventions. Furthermore, identiﬁcation and proper
treatment of asymptomatic cases (o200 parasites/ml), which
serve as transmission reservoirs, are critical for eliminating the
disease [10]. An assay that detects both pLDH and PfHRPII is
beneﬁcial for several reasons. First, pLDH is a parasite metabolic
enzyme, so it is present for infections resulting from any of the ﬁve
species of malaria known to infect humans, whereas PfHRPII is
only present in P. falciparum infections [11,12]. Thus, an assay that
detects both biomarkers can differentiate between P. falciparum
and non-falciparum infections, a distinction that determines
proper treatment [13]. Second, PfHRPII remains in host circulation
for up to one month, whereas pLDH is known to clear within 24 h
post parasite clearance, so a dual assay can distinguish resolved
and active P. falciparum infections [14]. The magnetic bead-based
simultaneous capture and sequential detection (SCSD) ELISA for
pLDH and PfHRPII would not only inform patient management, but
also allow for more efﬁcient and sensitive P. falciparum and non-
falciparum epidemiology and transmission studies. The presented
assay design is modular and can be applied to any set of two
biomarkers provided validated antibody pairs are available.2. Experimental
2.1. Reagents and materials
Dynabeadss MyOneTM Streptavidin T1 beads were purchased
from Life Technologies (Cat #65601). Recombinant P. falciparum
lactate dehydrogenase (rcPfLDH) and recombinant Plasmodium
vivax lactate dehydrogenase (rcPvLDH) were purchased from CTK
Biotech (Cat #A3005, #A3004). P. falciparum D6 strain was cul-
tured in the lab. P. falciparum W2, Benin 1, and PH1 reference
strains were obtained from the Foundation for Innovative New
Diagnostics (FIND). Anti-PfHRPII capture and detection antibodies
were purchased from Abcam (ab9203 and ab30384). Pan-speciﬁc
α-pLDH antibodies were purchased from AccessBio, Fitzgerald, and
Vista Diagnostics (Table S1). BluePhoss Microwell Phosphatase
substrate was purchased from KPL (#50-88-02), and TMB One was
purchased from Promega (G7431). The ELISA kit for pLDH was
purchased from SD Bioline, S. Korea (05EK40), and the ELISA kit for
PfHRPII was purchased from Cellabs, Australia (KM2).2.2. pLDH antibody pair screen
Capture and detection antibodies were screened for use in the
pLDH on-bead ELISA. Brieﬂy, 64 antibody pairs were tested (88
matrix) in a checkerboard 96-well plate ELISA format. Each of the
8 antibodies was conjugated to alkaline phosphatase (AP) for de-
tection (Abcam, ab102850). 100-ml solutions of 1 mg/ml unmodiﬁed
anti-pLDH IgG were incubated for one hour in Immulon 2 HB 96-
well plates (Thermo Scientiﬁc #3455). The plates were then wa-
shed 3 times with 1  phosphate buffered saline (PBS) containing
0.1% Tween-20 (PBST). Next, 250 ml of 5% w/v bovine serum al-
bumin (Fisher BP1600) in PBST was incubated for 2 h in each well.
The plates were then washed 3 times with PBST. Samples con-
sisting of 0 and 100 parasites/ml P. falciparum D6 culture or 0 and
500 pM rcPvLDH were added to the plates in triplicate in PBST
containing 0.1% BSA and incubated for 2 h. The plate was then
washed 5 times with 1  tris buffered saline (TBS) containing 0.1%
Tween-20 (TBST). Next, 100 ml of 0.5 mg/ml of detection antibodies
in TBST with 0.5% BSA was added to each well, and the plates were
incubated for 1 h while protected from light. The plates were then
washed 5 times with TBST, and 100 ml of BluePhoss Microwell
Phosphatase Substrate was added to each well and incubated for
20 min while protected from light. The absorbance was measured
at 620 nm using a Synergy H4 microplate reader. Signal-to-noise
ratios were determined for each pair and antigen.
2.3. Blood sample preparation
Pooled human whole blood (Bioreclamation IVT, HMWBCPD)
was spiked with D6 P. falciparum culture (at 18,450 parasites/ml) to
the desired parasitemia. An equal volume of 2  lysis buffer
(100 mM potassium phosphate pH 8.0, 600 mM NaCl, 250 mM
imidazole, 2% Triton-X-100) was then added, and the lysed blood
was ﬁltered through glass wool in a plastic syringe.
2.4. Preparation of mAb-functionalized magnetic beads
Target-speciﬁc antibody-functionalized beads were prepared as
reported previously [15]. Brieﬂy, α-pLDH (Vista, 19g7) or α-PfHRPII
(Abcam, ab9203) antibodies were biotinylated with EZ-Link NHS-
PEG4-Biotin, No-Weigh Format (Thermo Pierce #21329) in PBS
with a 20 excess of NHS-PEG4 Biotin. Remaining NHS-PEG4
biotin was removed using Zebra Spin Desalting Columns with a 7 K
molecular weight cut-off (Thermo Pierce #89882). Next, 5 mg of
Dynabeadss MyOne™ Streptavidin T1 was washed 3 times with
PBS before incubating for 30 min with 500 ml of 0.4 mg/ml of
biotinylated antibody in PBS. The beads were then washed 3 times
with PBS and blocked with excess D-biotin in PBS for 30 min. Fi-
nally, the beads were washed 3 times and re-suspended in 500 ml
of PBS with 0.01% Tween-20.
2.5. On-bead ELISA for pLDH
Solutions (200 ml) of parasitized lysed whole blood were placed
in a Fisherbrand Flat-bottom PS 96-well plate (#12565501). Four
ml HAMA blocker (Fitzgerald 85 R-1001), 10 ml of α-pLDH (19g7)
magnetic beads, and 1.57 ml of 1201:AP (1.27 mg/ml) were added
to each well and incubated on an orbital shaker for 15 min. Using a
MagWell™ Magnetic Separator (EdgeBio #57624), the beads were
separated from the supernatant and washed with 200 ml PBST. As a
second wash, 100 ml PBST was added to the beads, which were
then moved to new wells. Next, 100 ml BluePhoss Microwell
Phosphatase Substrate was added to each well containing beads,
and the plate was incubated for 15 min while protected from light.
The supernatant was removed, and signal was measured by ab-
sorbance (620 nm) on a plate reader.
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Parasitized lysed whole blood solutions (200 ml) were placed in
a Fisherbrand Flat-bottom PS 96-well plate. Four ml HAMA blocker,
5 ml of α-PfHRPII (ab9203) magnetic beads, and 2 ml of MPFG-55P
(0.1 mg/ml) were added to each well and incubated on an orbital
shaker for 15 min. Using a MagWell™ Magnetic Separator, the
beads were separated from the supernatant and washed with
200 ml PBST. As a second wash, 100 ml PBST were added to the
beads, which were then moved to new wells. Next, 100 ml TMB
One was added to each well containing beads, and the plate was
incubated for 5 min while protected from light. The supernatant
was removed, and the reaction was stopped with 100 ml of 2 M
H2SO4. Signal was measured by absorbance (450 nm) on a plate
reader.2.7. On-bead simultaneous capture and sequential detection (SCSD)
ELISA for pLDH and PfHRPII
Solutions (200 ml) of parasitized lysed whole blood were placed
in a Fisherbrand Flat-bottom PS 96-well plate. Four ml of HAMA
blocking reagent, 10 ml of 19g7-conjugated magnetic beads, 5 ml of
ab9203-conjugated magnetic beads, 1.57 ml of 1201:AP (1.27 mg/
ml), and 2 ml of ab30384 (0.1 mg/ml) were added to each well and
incubated on an orbital shaker for 15 min. The beads were pulled
to the sides of the wells using a MagWell™ Magnetic Separator,
and the supernatant was removed. The beads were washed with
200 ml PBST. As a second wash, 100 ml PBST were added to the
beads, which were then moved to new wells. Next, 100 ml of
BluePhoss Microwell Phosphatase Substrate was added to each
well and incubated for 15 min while protected from light. The
supernatant was removed and absorbance was measured at
620 nm (pLDH detection). The beads were then washed three
times with PBST and moved to new wells on the third wash. Next,
the beads were re-suspended in 100 ml of TMB One Solution and
incubated for 5 min while protected from light. Finally, the su-
pernatant was removed, and the reaction was quenched with
100 ml 2 M H2SO4 before absorbance was measured at 450 nm for
detection of PfHRPII. For both biomarkers, path length-corrected
absorbance vs. concentration was plotted, and limits of detections
(LODs) were calculated as the concentration at the minimum de-
tectable signal (3SDblankþsblank). See Fig. 1 for on-bead SCSD ELISA
workﬂow.Fig. 1. Workﬂow for on-bead SCSD2.8. Validation
Intra-assay variation for the developed assays was determined
by repeating standard curve measurements in triplicate (single-
plex assays) or sextuplicate (SCSD assay) on the same plate (one
user). The intra-assay variation (%CV) was found by taking the
average relative standard deviation (RSD) of each repeated mea-
surement. Inter-assay variation was determined by measuring
standard curves in triplicate (singleplex assays) or sextuplicate
(SCSD assay) over 5 days (one user). The inter-assay variation (%
CV) was calculated by dividing the standard deviation of all ab-
sorbance measurements at a given concentration over 5 days di-
vided the mean absorbance value at that concentration over the
5 days. For establishing inter-user variation, two users performed
standard curves in sextuplicate over 5 days. The inter-user varia-
tion (%CV) was calculated as the average percent difference be-
tween the mean values for both users across all replicates for all
days. Finally, the simplicity of the SCSD assay was evaluated by
providing 4 blinded samples (including a blank) to a novice user.
The user was allowed two practice rounds before measuring the
unknown samples via the on-bead SCSD ELISA for pLDH and
PfHRPII. Using a paired Student's T Test, novice absorbance values
for these samples were compared to the expected values from
standard curves generated by the inter-assay variation
measurements.3. Results and discussion
3.1. Design and optimization of on-bead ELISAs for pLDH and PfRHPII
Selection of the best capture and detection antibody pairs is
crucial for developing sensitive and speciﬁc immunoassays. For
PfHRPII assays, C1–13 (ab9203) capture and MPFG-55P, a detection
antibody conjugated to horseradish peroxidase (HRPx), have been
previously validated as an appropriate pair for ELISA formats [16].
Piper et al. performed extensive screening of pLDH antibody pairs
for immunochromatographic assays on nitrocellulose membranes
[17]. However, binding kinetics in a lateral ﬂow assay format do
not represent the same equilibrium kinetics found in ELISAs [18].
Thus, a comprehensive screening of antibody pairs was conducted
to evaluate performance in an ELISA format.
In total, 64 antibody pairs were screened (88 matrix) in a
checkerboard format. Each monoclonal antibody (Table S1) was
conjugated to alkaline phosphatase for detection. All antibodiesELISA for pLDH and PfHRPII.
Fig. 2. Pan-speciﬁc α-pLDH antibody pair screening results. Two candidate pairs
are highlighted in red. 19g7 capture and 1201 detection antibodies were chosen for
the pLDH on-bead ELISA.
Fig. 3. Standard curves for pLDH on-bead ELISA, measured at 620 nm, repeated in
triplicate over 5 days (black) and SD Bioline Malaria Ag ELISA, measured at 450 nm
(grey).
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PfLDH from P. falciparum D6 culture at 0 or 440 7 40 pM or
rcPvLDH at 0 or 500 pM. Detection antibodies were then added to
the plate, and signal was generated using a BCIP/NBT substrate.
The resulting signal-to-noise ratio for each pair and for each an-
tigen (Fig. S1) was normalized and plotted in Fig. 2. In this plot,
each point represents one antibody pair, where the abscissa is the
normalized signal-to-noise ratio for PfLDH, and the ordinate is the
normalized signal-to-noise ratio for rcPvLDH. An ideal antibody
pair would reside along the line y ¼ x in the upper right-hand
quadrant, indicating that it worked well for pLDH antigens from
both species. Based on these criteria, two candidate pairs were
identiﬁed and tested in an on-bead format (highlighted in red).
Both highlighted pairs included 19g7 as a capture antibody and
differed in detection antibodies (10-P09CS and 1201). Neither of
these pairs were tested by Piper et al., nor were they sold as
matched pairs from their respective manufacturer(s). However,
Piper et al. did show that 19g7 worked well for several pairs as a
capture antibody in a paper immunochromatographic assay for-
mat [17]. The pair with 19g7 capture and 1201:AP detection was
chosen for the on-bead format, because it displayed lower back-
ground signal in the on-bead ELISA format.
With antibody pairs selected for pLDH and PfHRPII, a one-step
on-bead ELISA was developed and optimized for each individual
biomarker. These individual assays were carried out by incubating
magnetic beads functionalized with capture antibodies as well as
enzyme-conjugated detection antibodies in samples consisting of
100 ml parasitized whole blood and 100 ml lysis buffer, allowing the
sandwich complexes to form on the surface of the particles. The
beads were then washed and re-suspended in the appropriate
detection antibody substrate, and colorimetric signal was mea-
sured by absorbance. In order to maximize signal-to-noise ratios,
several variables were optimized by varying the parameter of in-
terest while holding all other assay parameters constant (Figs. S2
and S3). First, the amount of magnetic beads for biomarker capture
was optimized to ensure there were enough binding sites to
capture all the biomarker available, while minimizing nonspeciﬁc
binding. Interestingly, for PfHRPII, as the amount of C1–13-con-
jugated beads was increased beyond 50 mg, we observed a re-
duction in signal-to-noise ratio, likely due to the unique protein
structure of PfHRPII (Fig. S3-A). Because its secondary structure issimply a series of repeat-motifs, several capture antibodies may
bind one PfHRPII antigen, causing aggregation of the magnetic
particles and preventing detection antibody from binding and
producing signal [19]. In contrast, we do not see a signiﬁcant de-
crease in signal-to-noise ratio for detection of pLDH when 19g7-
conjugated beads are increased above saturation, since pLDH does
not display repeated epitopes. Next, detection antibody con-
centration, sample incubation time, and substrate incubation time
were optimized for each biomarker. Ideal conditions for the pLDH
assay were found to be 100 mg 19g7-conjugated magnetic beads,
10 mg/ml 1201:AP detection antibody, 15-min sample incubation,
and 15-min incubation in BCIP/NBT. For the PfHRPII assay, 50 mg of
C1–13-functionalized magnetic beads, 1 mg/ml MPFG-55P detec-
tion antibody, 15-min sample incubation, and 5-min incubation in
TMB were chosen.
3.2. Performance of pLDH on-bead ELISA
The pLDH on-bead ELISA was performed in lysed whole blood
in triplicate, once per day over ﬁve days (Fig. 3). The linear range of
the assay was found to be 7.0–520 pM pLDH. The intra-assay var-
iation was 7.5%, and the inter-assay variation was 11%, below the
acceptable biomedical assay variation values of 15% [20]. The limit
of detection (LOD), deﬁned by the concentration at which the
signal is sblank þ 3SDblank, was 6.7 7 3.4 pM, corresponding to
about 5.2 parasites/ml of our in-house D6 P. falciparum culture, well
within the asymptomatic regime. This LOD is three times lower
than a commercially available well-plate ELISA kit for pLDH (Ma-
laria Ag ELISA, SD Bioline, LOD ¼ 19.3 7 0.7 pM). Further, while
the commercially available ELISA kit provides a pre-coated and
blocked microtiter plate, it still required over 2 h of incubation
time before results were generated. In contrast, our on-bead ELISA
for pLDH, which is an order of magnitude more sensitive, is
completed with a mere 30 min’ total incubation time.
3.3. Performance of PfHRPII on-bead ELISA
The PfHRPII on-bead ELISA was evaluated in lysed whole blood
in the same manner as the pLDH assay (Fig. 4). The linear range of
the assay was found to be 1.0–85 pM PfHRPII. The intra-assay
variation was 4%, and the inter-assay variation was 7%, well below
the acceptable value of 15% [20]. The LOD was 0.470.2 pM, cor-
responding to about 0.2 parasites/ml of our in-house D6 P. falci-
parum culture. This LOD for our 20-min PfHRPII on-bead ELISA is
over one order of magnitude lower than a 2.5-h commercially
available well-plate ELISA kit for PfHRPII (Malaria Antigen (HRP2)
Fig. 4. Standard curves for PfHRPII on-bead ELISA repeated in triplicate over 5 days
(black) and Cellabs Malaria Antigen (HRP2) CELISA (grey).
Fig. 5. Two-user validation curves for on-bead SCSD ELISA for (A) pLDH and (B)
PfHRPII. Novice measurements are highlighted in red. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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3.4. Design of on-bead SCSD ELISA for pLDH and PfHRPII
Fig. 1 shows the workﬂow for the on-bead SCSD ELISA. Before
combining the two independent assays into the dual format, it was
demonstrated that there was no cross-reactivity between pLDH
and the PfHRPII assay and vice versa (Fig. S4). To perform the SCSD
assay, magnetic particles functionalized with capture antibodies
for pLDH and PfHRPII were incubated in lysed whole blood sam-
ples along with the detection antibodies for each biomarker.
Throughout the assay, the beads for both biomarkers were pro-
cessed and washed simultaneously. The optimized bead masses
and detection antibody concentrations determined in the devel-
opment of the individual assays were also used in the SCSD for-
mat. A sample incubation time of 15 min was chosen, since this
time was found to be sufﬁcient for sandwich complex formation in
both the pLDH and PfHRPII assays. The beads were then washed
and re-suspended in BCIP/NBT for 15 min for the detection of
pLDH via the AP-conjugated detection antibody. Absorbance of the
supernatant was measured at 620 nm. It was found that AP de-
tection must precede HRPx detection, due to the pH sensitivity of
AP and the acidic nature of the HRPx substrate (Fig. S5). After
pLDH detection, the beads were washed and re-suspended in TMB
One solution for detection of PfHRPII. The reaction was stopped,
and PfHRPII signal was measured by absorbance at 450 nm. In this
work, the capture beads for the SCSD assay were prepared sepa-
rately for each biomarker; however, to facilitate large-scale SCSD
detection, a single batch of capture beads could be prepared using
the proper 2:1 ratio of pLDH to PfHRPII capture antibodies.
3.5. Performance of on-bead SCSD ELISA for pLDH and PfHRPII
The on-bead SCSD ELISA for pLDH and PfHRPII was evaluated
by two users measuring standard curves (n ¼ 6) once per day over
ﬁve days. A summary of the SCSD assay parameters for each bio-
marker is shown in Table 1. Linear ranges for each biomarker in
the SCSD format were unchanged compared to the individualTable 1
Performance of on-bead SCSD ELISA for pLDH and PfHRPII.
Parameter pLDH PfHRPII
Linear range 7 – 500 pM 1.5 – 80 pM
LOD 2.6 7 1.5 pM 1.6 7 1.0 pM
Intra-assay variability 3.9% 6.2%
Inter-assay variability 6.4% 12.6%
Inter-user variability 7.5% 20%assays. The intra- and inter- assay variabilities for pLDH and
PfHRPII detection remained below the accepted value of 15%. The
assay was reproducible between users for both biomarkers, with a
7.5% coefﬁcient of variation for pLDH and a 20% coefﬁcient of
variation for PfHRPII (Fig. 5). The simplicity of the assay was de-
termined by providing a novice user blinded samples and com-
paring the signal obtained to that of an expert user. The novice
measurements are highlighted in red in Fig. 5 and were not found
to be signiﬁcantly different from the expected absorbance values
predicted by standard curves from expert measurements by paired
T-tests (p ¼ 0.1699 and p ¼ 0.495 for pLDH and PfHRPII, respec-
tively). The LODs for pLDH and PfHRPII were 2.6 7 1.5 pM and
1.6 7 1.0 pM, corresponding to 2.0 and 0.9 parasites/ml, respec-
tively, for our in-house D6 P. falciparum culture. These detection
limits remain an order of magnitude lower than those of com-
mercially available ELISA kits for both biomarkers. Further, to de-
tect both biomarkers using commercially available kits, two ali-
quots of sample would need to be processed in parallel for a total
of more than 2 h before results are available. In contrast, the on-
bead SCSD ELISA for pLDH and PfHRPII measures both biomarkers
from the same sample with incubation times totaling just 35 min.
The broad applicability of the on-bead SCSD ELISA was de-
monstrated by performing the assay on three additional P. falci-
parum strains. Standardized culture specimens (W2, Benin 1, and
PH1 strains) designed for the development and evaluation of
PfHRPII diagnostics were obtained from the Foundation for In-
novative New Diagnostics (FIND). These standards were received
at a normalized concentration of 800 pg/ml PfHRPII, correspond-
ing to 14.4 pM and conﬁrmed in our laboratory with the com-
mercially available PfHRPII CELISA kit. These samples were diluted
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PfHRPII before lysis, and an on-bead SCSD ELISA was performed in
triplicate. The assay successfully detected both pLDH and PfHRPII
for all three strains tested, and the PfHRPII concentrations ob-
tained were not signiﬁcantly different from the FIND reference
values (Fig. S6). Because the assay performed well for multiple P.
falciparum strains, and the pLDH portion of the assay was opti-
mized for detection of the biomarker from both P. falciparum and P.
vivax, we expect the on-bead SCSD ELISA to perform reliably with
clinical samples.
Magnetic particle-based immunoassays have been developed
previously for pLDH and PfHRPII. For pLDH, magnetic micro-
particles were used to isolate Plasmodium falciparum lactate de-
hydrogenase (PfLDH) from lysed whole blood. The biomarker was
then detected using the Malstat assay, and enzymatic turnover
assay catalyzed by PfLDH [15]. The detection limit for this method
was 26 pM PfLDH, an order of magnitude higher than the devel-
oped on-bead SCSD ELISA for pLDH and PfHRPII. Further, we have
optimized the pLDH portion of the SCSD ELISA such that it can
detect pLDH for both P. falciparum and P. vivax. For PfHRPII, Cas-
tilho et al. developed an immunomagnetic detection strategy in
which a sandwich complex was formed on the surface of magnetic
micro- or nanoparticles [21]. Electrochemical and optical detection
strategies were used, and the limit of detection was found to be 12
pM, an order of magnitude higher than the dual on-bead SCSD
developed herein.
The developed on-bead SCSD ELISA is a rapid, simple, and
sensitive method to quantitatively measure two biomarkers. The
simultaneous capture aspect of the developed assay allows two
biomarkers to be measured from one sample, reducing the volume
of sample required (100 ml) to a single ﬁnger prick. The assay de-
tection limits are lower than traditional well plate ELISAs, and the
time-to-result is lower than currently available multiplexed im-
munoassays. Further, in contrast to commercially available multi-
plexed immunoassays, planar or suspension formats, the devel-
oped assay requires no laboratory equipment beyond what is re-
quired for conventional ELISAs. As such, it could be performed in
settings where automated, hospital-grade diagnostic systems are
impossible to implement due to lack of ﬁnancial resources or in-
frastructure, efﬁciently providing accurate results with more
clinical utility than traditional single-biomarker ELISAs. In the
context of malaria elimination, the rapid and accurate detection of
pLDH and PfHRPII using our on-bead SCSD ELISA would be useful
for several applications. For case management, the pLDH portion of
the assay determines whether or not a patient has an active ma-
laria infection, and the PfHRPII portion distinguishes between P.
falciparum and non-falciparum infections. Additionally, the LODs of
the developed assay are well within the asymptomatic regime,
allowing for detection and treatment of asymptomatic infections
that contribute to the malaria transmission reservoir and would
have otherwise been missed by commercially available ELISA kits
or rapid diagnostic tests [10,22]. Finally, our assay would be ad-
vantageous in the context of surveillance and intervention man-
agement, allowing rapid and sensitive measurement of disease
distribution and trends for both P. falciparum and non-falciparum
malaria.
While this work focused on detection of malarial biomarkers,
the format of the developed on-bead SCSD ELISA could be gen-
eralized to any disease for which the detection of two biomarkers
is advantageous. As long as a validated pair of antibodies is
available or can be found for each biomarker and cross-reactivity
between the two biomarkers is at a minimum, an on-bead SCSD
ELISA can be developed and optimized.4. Conclusions
We have developed a magnetic bead-based ELISA for the de-
tection of pLDH and PfHRPII in which sandwich complexes form on
the surface of the magnetic beads directly in lysed whole blood
samples. The biomarkers are detected sequentially in the appro-
priate detection enzyme substrates, with detection limits of
2.6 7 1.5 pM for pLDH and 1.6 7 1.0 pM for PfHRPII, an order of
magnitude better than commercially available ELISA kits for both
biomarkers and within the asymptomatic regime for malaria. The
low detection limits and high sensitivity of the assay can be at-
tributed to active mixing of the beads within the sample to avoid
mass transport limitations as well as careful assay optimization.
The on-bead SCSD ELISA is repeatable and reproducible across
multiple days and multiple users, and it is simple enough for no-
vice users to produce accurate results. As such, it would be a va-
luable tool for case management and disease surveillance in the
context of malaria elimination. Further, the developed on-bead
SCSD ELISA format could be applied to any disease in which the
detection of two biomarkers is beneﬁcial, provided that antibody
pairs are available for both biomarkers of interest.Acknowledgements
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